Back to News
Market Impact: 0.22
Kodiak Sciences Consensus Price Target Increased by 65.16% to $117.50
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
Kodiak Sciences' aggregate one-year analyst price target was raised to $117.50 per share from $71.14 on September 11, 2026, a 65.16% increase. The revision signals materially improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
KOD0.55
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October